Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.

@article{Conte1991CarboplatinDA,
  title={Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.},
  author={Pier Franco Conte and Milena Bruzzone and Flavio Carnino and Silvana Chiara and Michela Donadio and Vincenzo Facchini and Paolo Fioretti and Gerardo Foglia and Angiolo Gadducci and Luigi Gallo},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 4},
  pages={658-63}
}
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to receive cisplatin (CDDP) 50 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (PAC) or carboplatin 200 mg/mq, doxorubicin 45 mg/m2, and cyclophosphamide 600 mg/mq (CAC). To administer equitoxic doses at each cycle, the drug dosages were adjusted according to the hematologic toxicities experienced after the previous course; 44.7% of CAC and 21.1% of PAC patients required a dosage reduction… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
To administer equitoxic doses at each cycle , the drug dosages were adjusted according to the hematologic toxicities experienced after the previous course ; 44.7% of CAC and 21.1% of PAC patients required a dosage reduction at the second course ( P = .002 ) .
To administer equitoxic doses at each cycle , the drug dosages were adjusted according to the hematologic toxicities experienced after the previous course ; 44.7% of CAC and 21.1% of PAC patients required a dosage reduction at the second course ( P = .002 ) .
Neither CAC nor PAC caused any clinically relevant neuro - nephrotoxicity ; however , CDDP was administered with hydration and forced diuresis , while carboplatin was administered by rapid intravenous ( IV ) infusion .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
One hundred sixty - four patients with stage III - IV epithelial ovarian carcinoma were randomized to receive cisplatin ( CDDP ) 50 mg / mq , doxorubicin 45 mg / mq , and cyclophosphamide 600 mg / mq ( PAC ) or carboplatin 200 mg / mq , doxorubicin 45 mg / m2 , and cyclophosphamide 600 mg / mq ( CAC ) .
Carboplatin , doxorubicin , and cyclophosphamide versus cisplatin , doxorubicin , and cyclophosphamide : a randomized trial in stage III - IV epithelial ovarian carcinoma .
Median survivals and progression - free survivals ( PFSs ) were 22.6 and 13.2 months for PAC , and 23.1 and 15.5 months for CAC , respectively ; these differences are not significant .
All Topics